July 23, 2009 - Hospital Ambulance Service First to Use AutoPulse in New Zealand

HOSPITAL AMBULANCE SERVICE FIRST TO USE ZOLL AUTOPULSE IN NEW ZEALAND

Helps Save 69-Year-Old Woman in First Month of Use

July 23, 2009—CHELMSFORD, Mass.—ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, announced today that the Taranaki District Health Board Ambulance (TDHB) Service in Plymouth is the first service in New Zealand to install the ZOLL AutoPulse® Non-Invasive Cardiac Support Pump, which was used by paramedics to save the life of a 69-year-old woman experiencing sudden cardiac arrest (SCA) two weeks after installation.

According to Ian May, TDHB ambulance manager, the 69-year-old was discharged from the hospital after surviving sudden cardiac arrest. “We used the AutoPulse on her two or three times for about five minutes each when she re-arrested and were able to restore her pulse,” he said. “This device contributes significantly to the total management of critical care. It frees staff to concentrate on other aspects of resuscitating the patient, such as defibrillation, airway management, intubation, and drug therapy.”

“We know it works and it’s efficient,” May added. “It delivers effective, continuous CPR with near precision that can’t be accomplished by manual CPR. We’re excited that we will be able to add value to patient outcomes with the AutoPulse.”

“We’re extremely pleased that Taranaki was able to immediately witness the value the AutoPulse has in delivering consistent, high-quality chest compressions to improve outcomes from sudden cardiac arrest,” said Jonathan A. Rennert, President of ZOLL Medical Corporation. “The device also helps eliminate most of the interruptions typically encountered in CPR cases, including the need to stop compressions during transfers, and while going down narrow hallways and stairs, or while in elevators.”

The AutoPulseNon-invasive Cardiac Support Pump is an automated, portable device with an easy-to-use, load-distributing LifeBand® that squeezes the entire chest, improving blood flow to the heart and brain during sudden cardiac arrest (SCA). The AutoPulse offers a significant advantage over manual CPR in that it can move blood more effectively than manual chest compressions. AutoPulse delivers high-quality, uninterrupted chest compressions to maintain myocardial and cerebral perfusion. Additionally, it offers the benefit of freeing up rescuers to focus on other life-saving interventions.

Over 4,200 AutoPulse devices are in use in hospital and emergency service organizations worldwide.

About Sudden Cardiac Arrest

SCA, an abrupt disruption of the heart’s function, which causes a lack of blood flow to vital organs, claims more than 1 million lives each year. It is the leading cause of unexpected death in the world and strikes without warning. Currently, only about 5 percent of victims survive; 95 percent will die from SCA.

About Taranaki District Health Board Ambulance Service

Taranaki District Health Board (TDHB) Ambulance Service is a hospital-based ambulance service covering the province of Taranaki, with a population of 104,000. New Plymouth is the main city with 60,000 residents. Its fleet of 15 ambulances averages about 10,000 calls a year and frequently transports patients between the community’s two hospitals.

About ZOLL Medical Corporation

ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation and temperature control therapies for the treatment of critical care patients. With products for pacing, defibrillation, circulation, temperature management, and fluid resuscitation, ZOLL provides a comprehensive set of technologies, including Real CPR Help® and See-Thru CPR®, which help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.

ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia. During 2008 ZOLL marked the 25th anniversary of the Company’s resuscitation product development. For more information, visit www.zoll.com.

Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on May 8, 2009. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.